In August 2019, Lefamulin (XENLETA) received approval by FDA for the treatment of community-acquired bacterial pneumonia (CABP). One part of this drug contains Pleuromutilin — an antibiotic that inhibits protein synthesis in bacteria by binding to the peptidyl transferase component of the 50S subunit of ribosomes. The second part of the drug could be changed for amino-cyclohexane/benzene/heterocycle-thiol moieties. We have made a set of Building Blocks, which contain such parts — the perfect start for your research!